Ranbaxy gains nearly 1% as FDA approves Gurgaon & Romania R&D centres
Shares of Ranbaxy Laboratories Ltd. fell nearly 1 per cent in early trade on Bombay Stock Exchange (BSE) after reports suggested that US drug regulator inspected its two centres in Gurgaon & Romania R&D and cleared it.
The shares of company fell as much as 0.88 per cent to trade at Rs 471 a piece on the BSE. In a similar fashion, shares of the company fell 1.07 per cent to Rs 472.35 a piece on National Stock Exchange. Meanwhile, the broader benchmark Sensex was quoting at 22,717.06, up 14.72 points or 0.06 per cent at 10:27 hours.